Corpus Intelligence IC Memo — LAFAYETTE REGIONAL REHABILITATION HO 2026-04-26 09:56 UTC
IC Memo — LAFAYETTE REGIONAL REHABILITATION HO
Investment Committee Memorandum | IN | 40 beds | Grade C | EBITDA uplift $1.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LAFAYETTE REGIONAL REHABILITATION HO

CCN 153042 | TIPPECANOE, IN | 40 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LAFAYETTE REGIONAL REHABILITATION HO is a 40-bed suburban community hospital in TIPPECANOE, IN with $15.8M in net patient revenue and a 7.4% operating margin. The hospital serves a payer mix of 55.1% Medicare, 0.6% Medicaid, and 44.3% commercial.

Thesis: Turnaround. Our ML models identify $1.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 7.4% to 14.8% (+736bps).

Net Revenue HCRIS$15.8M
Current EBITDA COMPUTED$1.2M
Operating Margin COMPUTED7.4%
Occupancy HCRIS59.4%
Revenue / Bed COMPUTED$394K
Net-to-Gross HCRIS76.1%
Distress Probability ML52.4%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
90
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of 7.4% places it above the state median. Among 90 size-comparable peers (20-80 beds), the median margin is -2.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (20-80), prioritizing same-state peers. 90 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LAFAYETTE REGIONAL REHABILITAT (Target)IN40$15.8M7.4%
INDIANA ORTHOPAEDIC HOSPITAL LIN38$196.8M31.2%
LAPORTE HOSPITALIN74$192.4M19.3%
SCHNECK MEDICAL CENTERIN60$184.2M-0.8%
ORTHOPAEDIC HOSPT.AT PARKVIEWIN37$175.7M36.8%
LUTHERAN MUSCULOSKELETAL CENTEIN39$168.9M25.0%
WITHAM MEMORIAL HOSPITALIN50$158.5M-11.6%
FRANCISCAN HEALTH MOORESVILLEIN80$157.3M26.2%
MAJOR HOSPITALIN46$156.9M-9.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$331K+210bp18mo
Cost to Collect4.5%2.5%$315K+200bp12mo
Denial Rate Reduction12.0%6.5%$312K+198bp12mo
A/R Days Reduction5200.0%3800.0%$192K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$331K
Cost to Collect
$315K
Denial Rate Reduction
$312K
A/R Days Reduction
$192K
Clean Claim Rate
$10K
Total EBITDA Uplift$1.2M
Current EBITDA$1.2M
+ RCM Uplift+$1.2M
Pro Forma EBITDA$2.3M
Current Margin7.4%
Pro Forma Margin14.8%
WC Released (1x)$605K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.8M$19.3M10.73x60.8%
Base (11x exit)10.0x11.0x$1.8M$21.8M12.13x64.7%
Bull Case9.0x11.0x$1.6M$26.3M16.20x74.6%
Bull (12x exit)9.0x12.0x$1.6M$29.1M17.97x78.2%
Bear Case11.0x10.0x$2.0M$12.9M6.53x45.6%
Bear (11x exit)11.0x11.0x$2.0M$14.9M7.51x49.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 55.1% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
HighElevated distress probabilityModel estimates 52.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 90 hospitals with 20-80 beds
  • Same-state prioritization (n=91)
  • Comp margins: P25=-11.7% / P50=-2.9% / P75=7.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.